Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rallybio (RLYB) Liabilities and Shareholders Equity (2023 - 2025)

Rallybio's Liabilities and Shareholders Equity history spans 3 years, with the latest figure at $67.7 million for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 14.36% year-over-year to $67.7 million; the TTM value through Sep 2025 reached $135.8 million, down 30.24%, while the annual FY2024 figure was $68.1 million, 41.09% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $67.7 million at Rallybio, down from $68.1 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $162.3 million in Q1 2023 and bottomed at $67.7 million in Q3 2025.
  • The 3-year median for Liabilities and Shareholders Equity is $115.6 million (2023), against an average of $110.5 million.
  • The largest annual shift saw Liabilities and Shareholders Equity plummeted 41.09% in 2024 before it fell 14.36% in 2025.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $115.6 million in 2023, then tumbled by 41.09% to $68.1 million in 2024, then dropped by 0.66% to $67.7 million in 2025.
  • Per Business Quant, the three most recent readings for RLYB's Liabilities and Shareholders Equity are $67.7 million (Q3 2025), $68.1 million (Q4 2024), and $79.0 million (Q3 2024).